[HTML][HTML] Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for …
H Yoshioka, M Shimokawa, T Seto, S Morita… - Annals of …, 2019 - Elsevier
Background Primary analysis of the phase III study WJTOG 3405 demonstrated superiority of
progression-free survival (PFS) for gefitinib (G) in patients treated with the epidermal growth …
progression-free survival (PFS) for gefitinib (G) in patients treated with the epidermal growth …
Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with …
H Yoshioka, M Shimokawa, T Seto… - Annals of …, 2019 - annalsofoncology.org
Background Primary analysis of the phase III study WJTOG 3405 demonstrated superiority of
progression-free survival (PFS) for gefitinib (G) in patients treated with the epidermal growth …
progression-free survival (PFS) for gefitinib (G) in patients treated with the epidermal growth …
Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with …
H Yoshioka, M Shimokawa, T Seto… - Annals of …, 2019 - okayama.pure.elsevier.com
Background: Primary analysis of the phase III study WJTOG 3405 demonstrated superiority
of progression-free survival (PFS) for gefitinib (G) in patients treated with the epidermal …
of progression-free survival (PFS) for gefitinib (G) in patients treated with the epidermal …
Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with …
H Yoshioka, M Shimokawa, T Seto, S Morita… - Annals of Oncology …, 2019 - europepmc.org
BACKGROUND: Primary analysis of the phase III study WJTOG 3405 demonstrated
superiority of progression-free survival (PFS) for gefitinib (G) in patients treated with the …
superiority of progression-free survival (PFS) for gefitinib (G) in patients treated with the …
Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with …
H Yoshioka, M Shimokawa, T Seto… - Annals of oncology …, 2019 - pubmed.ncbi.nlm.nih.gov
Background Primary analysis of the phase III study WJTOG 3405 demonstrated superiority of
progression-free survival (PFS) for gefitinib (G) in patients treated with the epidermal growth …
progression-free survival (PFS) for gefitinib (G) in patients treated with the epidermal growth …
Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with …
H Yoshioka, M Shimokawa, T Seto… - Annals of …, 2019 - kyushu-u.elsevierpure.com
Background: Primary analysis of the phase III study WJTOG 3405 demonstrated superiority
of progression-free survival (PFS) for gefitinib (G) in patients treated with the epidermal …
of progression-free survival (PFS) for gefitinib (G) in patients treated with the epidermal …
[引用][C] Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients …
H Yoshioka, M Shimokawa, T Seto, S Morita… - Annals of …, 2019 - cir.nii.ac.jp
Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib
versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB/IV or …
versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB/IV or …
Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with …
H Yoshioka, M Shimokawa, T Seto… - Annals of …, 2019 - okayama.elsevierpure.com
Background: Primary analysis of the phase III study WJTOG 3405 demonstrated superiority
of progression-free survival (PFS) for gefitinib (G) in patients treated with the epidermal …
of progression-free survival (PFS) for gefitinib (G) in patients treated with the epidermal …
Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with …
H Yoshioka, M Shimokawa, T Seto… - Annals of …, 2019 - okayama.elsevierpure.com
Background: Primary analysis of the phase III study WJTOG 3405 demonstrated superiority
of progression-free survival (PFS) for gefitinib (G) in patients treated with the epidermal …
of progression-free survival (PFS) for gefitinib (G) in patients treated with the epidermal …